Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

SuperGreenToday Apr. 22 at 3:33 AM

$TCRX

0 · Reply

NoBox Apr. 21 at 4:28 PM

$TCRX Back to a dollar in a few days.

0 · Reply

StockScanners Apr. 21 at 2:53 AM

$TCRX keep watch if this holds above 1.39

1 · Reply

JSP_Dilution_Player Apr. 20 at 7:30 PM

$FATE $TCRX both did extremely well from alert 🚨

0 · Reply

signaljumper Apr. 20 at 5:29 PM

$TCRX around 1.80 and WE fill the Gap

1 · Reply

Partyflags Apr. 20 at 4:14 PM

$TCRX what is going on here 🤩🤩

0 · Reply

leis5 Apr. 20 at 3:55 PM

$TCRX Am not selling!

0 · Reply

kubota2323 Apr. 20 at 2:08 PM

$TCRX Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4 Lynx1 Capital Management LP 10% Owner Dec 19 '25 Buy 0.90 80,069 71,974 7,937,416 Dec 23 06:17 PM Lynx1 Capital Management LP 10% Owner Dec 22 '25 Buy 0.90 75,500 67,950 8,012,916 Dec 23 06:17 PM Lynx1 Capital Management LP 10% Owner Dec 23 '25 Buy 0.90 6,232 5,602 8,019,148 Dec 23 06:17 PM Lynx1 Capital Management LP 10% Owner May 19 '25 Buy 1.20 1,388,794 1,666,553 6,746,141 May 21 04:49 PM Lynx1 Capital Management LP 10% Owner May 20 '25 Buy 1.20 1,200,000 1,440,000

0 · Reply

kubota2323 Apr. 20 at 2:07 PM

$TCRX Owner Name Date Shares Held Change (Shares) Change (%) Value (In 1,000s) Lynx1 Capital Management Lp 12/31/2025 8,019,148 161,801 2.059% $9,543 Bvf Inc/Il 12/31/2025 5,226,074 0 0% $6,219 Baker Bros. Advisors Lp 12/31/2025 2,784,792 0 0% $3,314 Vanguard Group Inc 12/31/2025 2,475,733 157,817 6.809% $2,946 Blackrock, Inc. 12/31/2025 1,848,695 -534,069 -22.414% $2,200 Aberdeen Group Plc 12/31/2025 1,785,241 430,421 31.77% $2,124 Deer Management Co. Llc 12/31/2025 1,245,504 0 0% $1,482 Renaissance Technologies Llc 12/31/2025 1,141,069 311,150 37.492% $1,358 Two Sigma Investments, Lp 12/31/2025 651,179 231,775

0 · Reply

kubota2323 Apr. 20 at 2:06 PM

$TCRX added/adding

0 · Reply

TScan Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 7:00 AM EDT - 17 days ago

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 4, 2026, 11:50 AM EST - 7 weeks ago

TScan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 7:00 AM EST - 7 weeks ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 7:00 AM EST - 2 months ago

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Feb 25, 2026, 7:00 AM EST - 2 months ago

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Dec 8, 2025, 8:00 AM EST - 4 months ago

TScan Therapeutics Transcript: KOL Event

Dec 3, 2025, 4:05 PM EST - 5 months ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Nov 12, 2025, 10:00 AM EST - 5 months ago

TScan Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 7:00 AM EST - 5 months ago

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 6 months ago

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 8:00 AM EST - 6 months ago

TScan Therapeutics Transcript: FDA Announcement

Nov 3, 2025, 6:30 AM EST - 6 months ago

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Sep 17, 2025, 7:00 AM EDT - 7 months ago

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Sep 10, 2025, 9:00 AM EDT - 8 months ago

TScan Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 5:35 PM EDT - 8 months ago

TScan Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:00 AM EDT - 8 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2025, 7:00 AM EDT - 9 months ago

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 4, 2025, 4:55 PM EDT - 11 months ago

TScan Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 7:00 AM EDT - 11 months ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 13, 2025, 6:40 PM EDT - 1 year ago

TScan Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 4:53 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Apr 7, 2025, 9:30 AM EDT - 1 year ago

TScan Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mar 5, 2025, 1:10 PM EST - 1 year ago

TScan Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 10:00 AM EST - 1 year ago

TScan Therapeutics Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 18, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Dec 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 10, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Transcript: Status Update

Dec 9, 2024, 5:45 PM EST - 1 year ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 5, 2024, 9:15 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Sep 10, 2024, 9:00 AM EDT - 1 year ago

TScan Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 8:30 AM EDT - 1 year ago

TScan Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Updates to its Board of Directors

May 29, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 24, 2024, 4:05 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 2 years ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 2 years ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 2 years ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 2 years ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 2 years ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Jan 29, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 18, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Jan 4, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Dec 9, 2023, 12:00 PM EST - 2 years ago

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Dec 7, 2023, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

Dec 15, 2021, 4:30 PM EST - 4 years ago

TScan Therapeutics Transcript: Study Update

SuperGreenToday Apr. 22 at 3:33 AM

$TCRX

0 · Reply

NoBox Apr. 21 at 4:28 PM

$TCRX Back to a dollar in a few days.

0 · Reply

StockScanners Apr. 21 at 2:53 AM

$TCRX keep watch if this holds above 1.39

1 · Reply

JSP_Dilution_Player Apr. 20 at 7:30 PM

$FATE $TCRX both did extremely well from alert 🚨

0 · Reply

signaljumper Apr. 20 at 5:29 PM

$TCRX around 1.80 and WE fill the Gap

1 · Reply

Partyflags Apr. 20 at 4:14 PM

$TCRX what is going on here 🤩🤩

0 · Reply

leis5 Apr. 20 at 3:55 PM

$TCRX Am not selling!

0 · Reply

kubota2323 Apr. 20 at 2:08 PM

0 · Reply

kubota2323 Apr. 20 at 2:07 PM

0 · Reply

kubota2323 Apr. 20 at 2:06 PM

$TCRX added/adding

0 · Reply

MedicineMan777 Apr. 18 at 4:11 PM

$TCRX I heard Baker Brothers are in this then this will head towards 15 Billion market cap or 20X share price

0 · Reply

moneytome Apr. 17 at 4:46 PM

$TCRX nice breakout! I will close the gap around 1.8 if it breaks above 1.25. Very likely. $SCYX watch for continuation next two weeks. $VXRT watch for breaking above 0.8 and starting a new flag up to 1.4!

1 · Reply

Lima2111 Apr. 17 at 2:13 PM

$TCRX TScan trades at $65M against $119M net cash — the entire platform, incl. a FDA-agreed pivotal trial for TSC-101 in AML/MDS, two active pharma collabs with Amgen and Novartis, and a novel TCR-T platform validated by Baker Bros and BVF at 14-15% each, is priced negative at -$54M. The board has been deliberately assembled for a transaction: 1. Baker Bros partner Stephen Biggar chairs it 2. Garry Nicholson — who sat on the boards of four companies before their acquisitions by large pharma (BMS, Amgen, GSK, Pfizer) and is a former President of Pfizer Oncology — joined in June 2024, 3. Gabriela Gruia - Novartis-connected director gives the collaboration natural board-level oversight 4. Lynx1 at 14.36% provides the external activist forcing function with a typical 12-18 month exit horizon already well underway. The setup has every ingredient of a pre-announcement accumulation phase with a hard-to-justify downside and a well-defined catalyst path to value realization.

0 · Reply

suredubb Apr. 16 at 8:08 PM

$TCRX nice day of accumulation… when the big buys happen, are the days you don’t want to miss

0 · Reply

suredubb Apr. 16 at 2:42 AM

$TCRX fireside chat awesome… drug saves lives huge market and profit potential updates in 2 months will be huge for company.. they seem excited to share future data around June

0 · Reply